Essais cliniques

Sans recherche, pas de nouveaux traitements! Or, l’Institut de cardiologie de l’Université d’Ottawa (ICUO) est à cet égard un terrain d’autant plus fertile que sa recherche, si elle s’amorce et s’achève comme toute autre dans un laboratoire, a la particularité de se poursuivre et de se compléter au chevet des patients.

Jusqu’à 200 essais cliniques se déroulent à tout moment à l’ICUO à différentes étapes des études en cours. Nous sommes parfois à l’origine de ces études et les seuls à les mener. Nous collaborons aussi avec d’autres établissements à de vastes recherches d’envergure nationale ou internationale, qu’il nous arrive de diriger. Chaque année, des milliers de volontaires, pour la plupart des patients, mais aussi des personnes en bonne santé, participent à nos études. À l’heure actuelle, 50 scientifiques et chercheurs cliniques mènent des essais cliniques dans nos locaux.

Pour plus d’informations, contactez JoinAStudy@ottawaheart.ca

Essais cliniques à l’Institut de cardiologie de l’Université d’Ottawa (en anglais seulement)

Filter Status:
Status Study
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  • Conditions: Atrial Fibrillation
  • Sponsor: Biosense Webster, Inc.
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

The STOP-MED CTRCD Trial

  • Conditions: Heart Failure Cardiotoxicity Cardiac Toxicity Antineoplastics Toxicity Cancer
  • Sponsor: University Health Network, Toronto Unity Health Toronto Hamilton Health Sciences Corporation St. Boniface Hospital University of Alberta University of Ottawa Heart Institute, Canada University College London Hospitals Alberta Health Services, Calgary Brigham and Women's Hospital Baker Heart and Diabetes Institute
Recruiting

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

  • Conditions: Non-melanoma Skin Cancer Carcinoma, Squamous Cell Carcinoma, Basal Cell Keratinocyte Carcinoma
  • Sponsor: Women's College Hospital Canadian Institutes of Health Research (CIHR) University Health Network, Toronto NOW Foods
Recruiting

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

  • Conditions: Non-melanoma Skin Cancer Carcinoma, Squamous Cell Carcinoma, Basal Cell Keratinocyte Carcinoma
  • Sponsor: Women's College Hospital Canadian Institutes of Health Research (CIHR) University Health Network, Toronto NOW Foods
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

An Interactive Smartphone Application to Motivate Smokers to Quit

  • Conditions: Smoking Cessation Smoking Behaviors
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

An Interactive Smartphone Application to Motivate Smokers to Quit

  • Conditions: Smoking Cessation Smoking Behaviors
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

An Interactive Smartphone Application to Motivate Smokers to Quit

  • Conditions: Smoking Cessation Smoking Behaviors
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

An Interactive Smartphone Application to Motivate Smokers to Quit

  • Conditions: Smoking Cessation Smoking Behaviors
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  • Conditions: Acute Myocardial Infarction Coronary Artery Disease
  • Sponsor: Population Health Research Institute
Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  • Conditions: Acute Myocardial Infarction Coronary Artery Disease
  • Sponsor: Population Health Research Institute
Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  • Conditions: Acute Myocardial Infarction Coronary Artery Disease
  • Sponsor: Population Health Research Institute
Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  • Conditions: Acute Myocardial Infarction Coronary Artery Disease
  • Sponsor: Population Health Research Institute
Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  • Conditions: Acute Myocardial Infarction Coronary Artery Disease
  • Sponsor: Population Health Research Institute
Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  • Conditions: Acute Myocardial Infarction Coronary Artery Disease
  • Sponsor: Population Health Research Institute
Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  • Conditions: Acute Myocardial Infarction Coronary Artery Disease
  • Sponsor: Population Health Research Institute
Recruiting

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  • Conditions: Acute Myocardial Infarction Coronary Artery Disease
  • Sponsor: Population Health Research Institute
Recruiting

A Study to Test Asundexian to Prevent a Clot-related Stroke in Participants After an Acute Ischemic Stroke or High-risk TIA/Mini-stroke (Transient Ischemic Attack)

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian to Prevent a Clot-related Stroke in Participants After an Acute Ischemic Stroke or High-risk TIA/Mini-stroke (Transient Ischemic Attack)

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  • Conditions: Prevention of Ischemic Stroke Acute Non-cardioembolic Ischemic Stroke High-risk Transient Ischemic Attack
  • Sponsor: Bayer
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  • Conditions: Atopic Dermatitis
  • Sponsor: Amgen
Recruiting

Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises

  • Conditions: Coronary Artery Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises

  • Conditions: Coronary Artery Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises

  • Conditions: Coronary Artery Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises

  • Conditions: Coronary Artery Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

  • Conditions: Cardiomyopathy, Hypertrophic
  • Sponsor: Bristol-Myers Squibb
Recruiting

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

  • Conditions: Cardiomyopathy, Hypertrophic
  • Sponsor: Bristol-Myers Squibb
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

  • Conditions: Bleeding Cardiac Surgery Patients
  • Sponsor: Octapharma
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

  • Conditions: Bleeding Cardiac Surgery Patients
  • Sponsor: Octapharma
Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  • Conditions: Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis Immune-Mediated Necrotizing Myopathy Antisynthetase Syndrome
  • Sponsor: argenx
Recruiting

Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

  • Conditions: Bleeding Cardiac Surgery Patients
  • Sponsor: Octapharma
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  • Conditions: Triple Negative Breast Cancer PD-L1 Negative
  • Sponsor: Gilead Sciences
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Card

  • Conditions: Coronary Artery Disease
  • Sponsor: Novartis Pharmaceuticals
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  • Conditions: Shock, Cardiogenic
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Aggressive Smoking Cessation Trial (ASAP)

  • Conditions: Acute Coronary Syndrome
  • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting

Aggressive Smoking Cessation Trial (ASAP)

  • Conditions: Acute Coronary Syndrome
  • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting

Aggressive Smoking Cessation Trial (ASAP)

  • Conditions: Acute Coronary Syndrome
  • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting

Aggressive Smoking Cessation Trial (ASAP)

  • Conditions: Acute Coronary Syndrome
  • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting

Aggressive Smoking Cessation Trial (ASAP)

  • Conditions: Acute Coronary Syndrome
  • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting

Aggressive Smoking Cessation Trial (ASAP)

  • Conditions: Acute Coronary Syndrome
  • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Recruiting

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

  • Conditions: Coronary Artery Disease
  • Sponsor: MedTrace Pharma A/S
Recruiting

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

  • Conditions: Coronary Artery Disease
  • Sponsor: MedTrace Pharma A/S
Recruiting

Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  • Conditions: Atrial Fibrillation Heart Failure
  • Sponsor: Anthony Tang
Recruiting

Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  • Conditions: Atrial Fibrillation Heart Failure
  • Sponsor: Anthony Tang
Recruiting

Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  • Conditions: Atrial Fibrillation Heart Failure
  • Sponsor: Anthony Tang
Recruiting

Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  • Conditions: Atrial Fibrillation Heart Failure
  • Sponsor: Anthony Tang
Recruiting

Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  • Conditions: Atrial Fibrillation Heart Failure
  • Sponsor: Anthony Tang
Recruiting

Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend

  • Conditions: Atrial Fibrillation Heart Failure
  • Sponsor: Anthony Tang
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  • Conditions: Stroke Patent Foramen Ovale
  • Sponsor: Occlutech International AB
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  • Conditions: Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma Metastatic Rhabdomyosarcoma Solid Alveolar Rhabdomyosarcoma Spindle Cell Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  • Conditions: Primary Mediastinal Large B-Cell Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Conditions: Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome
  • Sponsor: LLS PedAL Initiative, LLC Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

  • Conditions: Recurrent Low Grade Astrocytoma Recurrent WHO Grade 2 Glioma Refractory Low Grade Astrocytoma Refractory Low Grade Glioma Refractory WHO Grade 1 Glioma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

  • Conditions: Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8
  • Sponsor: NRG Oncology National Cancer Institute (NCI)
Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

  • Conditions: Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8
  • Sponsor: NRG Oncology National Cancer Institute (NCI)
Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

  • Conditions: Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8
  • Sponsor: NRG Oncology National Cancer Institute (NCI)
Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

  • Conditions: Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8
  • Sponsor: NRG Oncology National Cancer Institute (NCI)
Recruiting

Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR)

  • Conditions: Nonvalvular Atrial Fibrillation Severe Degenerative Mitral Regurgitation
  • Sponsor: Mayo Clinic
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  • Conditions: Atrial Fibrillation
  • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Montreal Heart Institute
Recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Conditions: Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

  • Conditions: Hemorrhage Urgent Surgery Invasive Procedure
  • Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

  • Conditions: Hemorrhage Urgent Surgery Invasive Procedure
  • Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

  • Conditions: Hemorrhage Urgent Surgery Invasive Procedure
  • Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

  • Conditions: Hemorrhage Urgent Surgery Invasive Procedure
  • Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

  • Conditions: Hemorrhage Urgent Surgery Invasive Procedure
  • Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

  • Conditions: Hemorrhage Urgent Surgery Invasive Procedure
  • Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

  • Conditions: Hemorrhage Urgent Surgery Invasive Procedure
  • Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

  • Conditions: Hemorrhage Urgent Surgery Invasive Procedure
  • Sponsor: SFJ Pharmaceuticals, Inc.
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  • Conditions: Pulmonary Arterial Hypertension
  • Sponsor: Actelion
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
  • Sponsor: National Cancer Institute (NCI)
Recruiting

Amplatzer Amulet LAAO vs. NOAC

  • Conditions: Atrial Fibrillation Stroke Bleeding
  • Sponsor: Abbott Medical Devices
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

  • Conditions: Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Valve Disease
  • Sponsor: Edwards Lifesciences
Recruiting

MRI Assessment of Pulmonary Edema in Acute Heart Failure

  • Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure
  • Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting

MRI Assessment of Pulmonary Edema in Acute Heart Failure

  • Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure
  • Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting

MRI Assessment of Pulmonary Edema in Acute Heart Failure

  • Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure
  • Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting

MRI Assessment of Pulmonary Edema in Acute Heart Failure

  • Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure
  • Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting

MRI Assessment of Pulmonary Edema in Acute Heart Failure

  • Conditions: Acute Heart Failure Pulmonary Edema With Heart Failure
  • Sponsor: University of Alberta Canadian Institutes of Health Research (CIHR)
Recruiting

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

  • Conditions: Stroke Atrial Fibrillation
  • Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

  • Conditions: Stroke Atrial Fibrillation
  • Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

  • Conditions: Stroke Atrial Fibrillation
  • Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

  • Conditions: Stroke Atrial Fibrillation
  • Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

  • Conditions: Stroke Atrial Fibrillation
  • Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

  • Conditions: Stroke Atrial Fibrillation
  • Sponsor: Population Health Research Institute Hamilton Health Sciences Corporation
Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  • Conditions: Intracranial Hemorrhages Atrial Fibrillation
  • Sponsor: Population Health Research Institute
Recruiting

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  • Conditions: Intracranial Hemorrhages Atrial Fibrillation
  • Sponsor: Population Health Research Institute
Recruiting

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  • Conditions: Intracranial Hemorrhages Atrial Fibrillation
  • Sponsor: Population Health Research Institute
Recruiting

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  • Conditions: Intracranial Hemorrhages Atrial Fibrillation
  • Sponsor: Population Health Research Institute
Recruiting

EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  • Conditions: Intracranial Hemorrhages Atrial Fibrillation
  • Sponsor: Population Health Research Institute
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  • Conditions: B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Down Syndrome
  • Sponsor: National Cancer Institute (NCI)
Recruiting

TRILUMINATE Pivotal Trial

  • Conditions: Tricuspid Regurgitation
  • Sponsor: Abbott Medical Devices
Recruiting

TRILUMINATE Pivotal Trial

  • Conditions: Tricuspid Regurgitation
  • Sponsor: Abbott Medical Devices
Recruiting

TRILUMINATE Pivotal Trial

  • Conditions: Tricuspid Regurgitation
  • Sponsor: Abbott Medical Devices
Recruiting

TRILUMINATE Pivotal Trial

  • Conditions: Tricuspid Regurgitation
  • Sponsor: Abbott Medical Devices
Recruiting

TRILUMINATE Pivotal Trial

  • Conditions: Tricuspid Regurgitation
  • Sponsor: Abbott Medical Devices
Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  • Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  • Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  • Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  • Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  • Conditions: Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD

  • Conditions: Peripheral Arterial Disease
  • Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting

Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD

  • Conditions: Peripheral Arterial Disease
  • Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting

Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD

  • Conditions: Peripheral Arterial Disease
  • Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting

Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD

  • Conditions: Peripheral Arterial Disease
  • Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting

Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD

  • Conditions: Peripheral Arterial Disease
  • Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting

Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD

  • Conditions: Peripheral Arterial Disease
  • Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting

Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life & Cardiovascular Risk in People With PAD

  • Conditions: Peripheral Arterial Disease
  • Sponsor: Ottawa Heart Institute Research Corporation AFP Innovation Fund
Recruiting

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

  • Conditions: Ascending Aortic Aneurysm Enlargement Ascending Aorta Aneurysm
  • Sponsor: Ottawa Heart Institute Research Corporation University of Calgary
Recruiting

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

  • Conditions: Ascending Aortic Aneurysm Enlargement Ascending Aorta Aneurysm
  • Sponsor: Ottawa Heart Institute Research Corporation University of Calgary
Recruiting

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

  • Conditions: Ascending Aortic Aneurysm Enlargement Ascending Aorta Aneurysm
  • Sponsor: Ottawa Heart Institute Research Corporation University of Calgary
Recruiting

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

  • Conditions: Ascending Aortic Aneurysm Enlargement Ascending Aorta Aneurysm
  • Sponsor: Ottawa Heart Institute Research Corporation University of Calgary
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

  • Conditions: Breast Cancer
  • Sponsor: Canadian Cancer Trials Group Alliance for Clinical Trials in Oncology Eastern Cooperative Oncology Group NRG Oncology SWOG Cancer Research Network
Recruiting

Prospective Urban Rural Epidemiology Study

  • Conditions: Cardiovascular Diseases Risk Factor, Cardiovascular Health Behavior Environmental Exposure Lung Diseases Cancer Injuries Renal Disease Communicable Disease
  • Sponsor: Population Health Research Institute Canadian Institutes of Health Research (CIHR) Heart and Stroke Foundation of Ontario
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

  • Conditions: Carcinoma In Situ Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Biomarker Guided Discharge of Heart Failure Patients

  • Conditions: Heart Failure With Decompensation
  • Sponsor: Peter Liu Genome Canada Roche Diagnostics Ottawa Heart Institute Research Corporation
Recruiting

Biomarker Guided Discharge of Heart Failure Patients

  • Conditions: Heart Failure With Decompensation
  • Sponsor: Peter Liu Genome Canada Roche Diagnostics Ottawa Heart Institute Research Corporation
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  • Conditions: Childhood Extracranial Germ Cell Tumor Extragonadal Embryonal Carcinoma Germ Cell Tumor Malignant Germ Cell Tumor Malignant Ovarian Teratoma Stage I Ovarian Choriocarcinoma Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage I Ovarian Teratoma AJCC v6 and v7 Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage I Testicular Choriocarcinoma AJCC v6 and v7 Stage I Testicular Embryonal Carcinoma AJCC v6 and v7 Stage I Testicular Seminoma AJCC v6 and v7 Stage I Testicular Yolk Sac Tumor AJCC v6 and v7 Stage II Ovarian Choriocarcinoma Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage II Testicular Choriocarcinoma AJCC v6 and v7 Stage II Testicular Embryonal Carcinoma AJCC v6 and v7 Stage II Testicular Yolk Sac Tumor AJCC v6 and v7 Stage III Ovarian Choriocarcinoma Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7 Stage III Testicular Choriocarcinoma AJCC v6 and v7 Stage III Testicular Embryonal Carcinoma AJCC v6 and v7 Stage III Testicular Yolk Sac Tumor AJCC v6 and v7 Stage IV Ovarian Choriocarcinoma Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7 Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7 Testicular Mixed Choriocarcinoma and Embryonal Carcinoma Testicular Mixed Choriocarcinoma and Teratoma Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Conditions: Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia
  • Sponsor: Children's Oncology Group EsPhALL Network/ BFM Study Group National Cancer Institute (NCI)
Recruiting

Comparing Hypothermic Temperatures During Hemiarch Surgery

  • Conditions: Thoracic Aortic Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Comparing Hypothermic Temperatures During Hemiarch Surgery

  • Conditions: Thoracic Aortic Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Comparing Hypothermic Temperatures During Hemiarch Surgery

  • Conditions: Thoracic Aortic Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Comparing Hypothermic Temperatures During Hemiarch Surgery

  • Conditions: Thoracic Aortic Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Comparing Hypothermic Temperatures During Hemiarch Surgery

  • Conditions: Thoracic Aortic Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Comparing Hypothermic Temperatures During Hemiarch Surgery

  • Conditions: Thoracic Aortic Disease
  • Sponsor: Ottawa Heart Institute Research Corporation
Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

  • Conditions: Community-acquired Pneumonia, Influenza, COVID-19
  • Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

  • Conditions: Community-acquired Pneumonia, Influenza, COVID-19
  • Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

  • Conditions: Community-acquired Pneumonia, Influenza, COVID-19
  • Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

  • Conditions: Community-acquired Pneumonia, Influenza, COVID-19
  • Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

  • Conditions: Community-acquired Pneumonia, Influenza, COVID-19
  • Sponsor: UMC Utrecht Australian and New Zealand Intensive Care Research Centre Medical Research Institute of New Zealand Unity Health Berry Consultants Global Coalition for Adaptive Research University of Pittsburgh Medical Center Intensive Care National Audit & Research Centre St. Marianna University School of Medicine National Intensive Care Surveillance MORU National University Hospital, Singapore
Recruiting

Project: Every Child for Younger Patients With Cancer

  • Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Project: Every Child for Younger Patients With Cancer

  • Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Project: Every Child for Younger Patients With Cancer

  • Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Project: Every Child for Younger Patients With Cancer

  • Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Project: Every Child for Younger Patients With Cancer

  • Conditions: Carcinoma In Situ Central Nervous System Neoplasm Childhood Immature Teratoma Childhood Langerhans Cell Histiocytosis Childhood Mature Teratoma Congenital Mesoblastic Nephroma Desmoid Fibromatosis Ganglioneuroma Lymphoproliferative Disorder Malignant Solid Neoplasm Melanocytic Neoplasm Myeloproliferative Neoplasm Neuroendocrine Neoplasm Stromal Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Conditions: Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  • Conditions: Ganglioneuroblastoma Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Regional Neuroblastoma Stage 4 Neuroblastoma Stage 4S Neuroblastoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  • Conditions: Ganglioneuroblastoma Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Regional Neuroblastoma Stage 4 Neuroblastoma Stage 4S Neuroblastoma
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  • Conditions: Myocardial Infarction Sudden Death
  • Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  • Conditions: Myocardial Infarction Sudden Death
  • Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  • Conditions: Myocardial Infarction Sudden Death
  • Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  • Conditions: Myocardial Infarction Sudden Death
  • Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  • Conditions: Myocardial Infarction Sudden Death
  • Sponsor: University of Calgary Canadian Institutes of Health Research (CIHR) Alberta Innovation and Science Medtronic GE Healthcare Cardiac Arrhythmia Network of Canada Accelerating Clinical Trials Consortium
Recruiting

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)
Recruiting

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  • Conditions: Childhood Malignant Neoplasm
  • Sponsor: Children's Oncology Group National Cancer Institute (NCI)